4'-Methoxy-3',5-di-2-propenyl-(1,1'-biphenyl)-2-ol manufacturers
- 4-O-Methyl honokiol
-
- $52.00 / 1mg
-
2025-11-07
- CAS:68592-15-4
- Min. Order:
- Purity: 99.31%
- Supply Ability: 10g
- 4-O-Methyl honokiol
-
- $52.00 / 1mg
-
2025-10-26
- CAS:68592-15-4
- Min. Order:
- Purity: 99.31%
- Supply Ability: 10g
- 4-O-Methyl honokiol
-
- $52.00 / 1mg
-
2025-07-10
- CAS:68592-15-4
- Min. Order:
- Purity: 99.31%
- Supply Ability: 10g
|
| | 4'-Methoxy-3',5-di-2-propenyl-(1,1'-biphenyl)-2-ol Basic information |
| | 4'-Methoxy-3',5-di-2-propenyl-(1,1'-biphenyl)-2-ol Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 33 mg/ml; DMSO: 33 mg/ml; Ethanol: 33 mg/ml; Ethanol:PBS (pH 7.2) (1:2): 0.3 mg/ml | | form | Viscous Liquid | | color | Orange to red |
| | 4'-Methoxy-3',5-di-2-propenyl-(1,1'-biphenyl)-2-ol Usage And Synthesis |
| Uses | 4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a PPARγ agonist, and inhibtis NF-κB activity, used for cancer and inflammation research. | | in vivo | 4-O-Methyl honokiol (40 or 80 mg/kg, i.p. everyday for 4 weeks) inhibits the growth of SW620 and PC3 tumours in SW620 and PC3 xenograft model. 4-O-Methyl honokiol significantly increases the expression of p21 and PPARγ in the tumour tissues[1]. 4-O-Methyl honokiol (0.5 or 1 mg/kg/day daily for 3 weeks) significantly ameliorates LPS-induced memory impairment, and inhibits LPS-induced iNOS and COX-2 expression in mice. 4-O-Methyl honokiol also shows inhibitory activities against the Aβ1-42 accumulation, and activates astrocytes and microglia in LPS-injected mice brain[2]. | | IC 50 | PPARγ; NF-κB | | References | [1] Lee NJ, et al. 4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity. Br J Pharmacol. 2013 Mar;168(5):1133-45. DOI:10.1111/j.1476-5381.2012.02235.x
[2] Lee YJ, et al. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation. 2012 Feb 19;9:35. DOI:10.1186/1742-2094-9-35 |
| | 4'-Methoxy-3',5-di-2-propenyl-(1,1'-biphenyl)-2-ol Preparation Products And Raw materials |
|